期刊
JOURNAL OF NUCLEAR MEDICINE
卷 52, 期 1, 页码 81-89出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.110.077941
关键词
genitourinary; molecular imaging; PET; PET/CT; acetate; choline; FDG; prostate
资金
- National Institutes of Health-National Cancer Institute [R01-CA111613, R21-CA142426]
- NATIONAL CANCER INSTITUTE [R21CA142426, R01CA111613] Funding Source: NIH RePORTER
Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. The role of imaging in prostate cancer should include diagnosis, localization, and characterization (indolent vs. lethal) of the primary tumor, determination of extracapsular spread, guidance and evaluation of local therapy in organ-confined disease, staging of locoregional lymph nodes, detection of locally recurrent and metastatic disease in biochemical relapse, planning of radiation treatment, prediction and assessment of tumor response to salvage and systemic therapy, monitoring of active surveillance and definition of a trigger for definitive therapy, and prognostication of time to hormone refractoriness in castrate disease and overall survival. To address these tasks effectively, imaging needs to be tailored to the specific phases of the disease in a patient-specific, risk-adjusted manner. In this article, I review the preclinical and clinical evidence on the potential and emerging role of PET with the 3 most commonly studied radiotracers in prostate cancer, namely F-18-FDG, F-18-or C-11-acetate, and F-18-or C-11-choline.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据